JP2021523213A - 癌を治療する方法 - Google Patents

癌を治療する方法 Download PDF

Info

Publication number
JP2021523213A
JP2021523213A JP2020564674A JP2020564674A JP2021523213A JP 2021523213 A JP2021523213 A JP 2021523213A JP 2020564674 A JP2020564674 A JP 2020564674A JP 2020564674 A JP2020564674 A JP 2020564674A JP 2021523213 A JP2021523213 A JP 2021523213A
Authority
JP
Japan
Prior art keywords
icos
cells
cancer therapies
antibody
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020564674A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523213A5 (https=
JPWO2019222188A5 (https=
Inventor
クリストファー ハーヴェイ，
クリストファー ハーヴェイ，
デボラ ロー，
デボラ ロー，
アマンダ， エリザベス ハンソン，
アマンダ， エリザベス ハンソン，
マーティン， ユー ファン，
マーティン， ユー ファン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jounce Therapeutics Inc
Original Assignee
Jounce Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jounce Therapeutics Inc filed Critical Jounce Therapeutics Inc
Publication of JP2021523213A publication Critical patent/JP2021523213A/ja
Publication of JP2021523213A5 publication Critical patent/JP2021523213A5/ja
Publication of JPWO2019222188A5 publication Critical patent/JPWO2019222188A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020564674A 2018-05-14 2019-05-14 癌を治療する方法 Pending JP2021523213A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862671181P 2018-05-14 2018-05-14
US62/671,181 2018-05-14
US201862679346P 2018-06-01 2018-06-01
US62/679,346 2018-06-01
US201862750026P 2018-10-24 2018-10-24
US62/750,026 2018-10-24
US201962827312P 2019-04-01 2019-04-01
US62/827,312 2019-04-01
PCT/US2019/032184 WO2019222188A1 (en) 2018-05-14 2019-05-14 Methods of treating cancer

Publications (3)

Publication Number Publication Date
JP2021523213A true JP2021523213A (ja) 2021-09-02
JP2021523213A5 JP2021523213A5 (https=) 2022-05-20
JPWO2019222188A5 JPWO2019222188A5 (https=) 2022-05-20

Family

ID=66690990

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020564674A Pending JP2021523213A (ja) 2018-05-14 2019-05-14 癌を治療する方法

Country Status (5)

Country Link
US (2) US11292840B2 (https=)
EP (1) EP3793598A1 (https=)
JP (1) JP2021523213A (https=)
CN (1) CN112703012A (https=)
WO (1) WO2019222188A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025160816A (ja) * 2024-04-10 2025-10-23 イミューンオンコ バイオファーマシューティカルズ （シャンハイ） インコーポレイテッド 古典的ホジキンリンパ腫に対する併用療法

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
CA2890346A1 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
EP2945652B1 (en) 2013-01-18 2021-07-07 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
US20200024351A1 (en) * 2017-04-03 2020-01-23 Jounce Therapeutics, Inc. Compositions and Methods for the Treatment of Cancer
EP3870610A1 (en) * 2018-10-24 2021-09-01 Jounce Therapeutics, Inc. Methods and compositions for the treatment of cancer and infectious diseases
EP4058593A4 (en) 2019-11-12 2023-11-15 Foundation Medicine, Inc. METHODS FOR DETECTING A FUSION GENE ENCODING A NEO-ANTIGEN
JP2023510847A (ja) * 2020-01-13 2023-03-15 ジャウンス セラピューティックス， インク． 癌の治療方法
AU2021260553A1 (en) * 2020-04-20 2022-10-20 Jounce Therapeutics, Inc. Compositions and methods for vaccination and the treatment of infectious diseases
GB202007099D0 (en) 2020-05-14 2020-07-01 Kymab Ltd Tumour biomarkers for immunotherapy
CN112807425A (zh) * 2021-01-14 2021-05-18 南方医科大学深圳医院 一种tTIM融合蛋白疫苗、制备方法及应用
US20220396623A1 (en) 2021-05-18 2022-12-15 Kymab Limited Uses of anti-icos antibodies
WO2022272309A1 (en) 2021-06-25 2022-12-29 Foundation Medicine, Inc. Methods of using somatic hla-i loh to predict response of immune checkpoint inhibitor-treated patients with lung cancer
US20250340641A1 (en) 2022-05-18 2025-11-06 Kymab Limited Uses of anti-icos antibodies
CN118516308B (zh) * 2024-07-22 2024-10-22 深圳市中佳生物医疗科技有限公司 免疫调节剂在制备增强nk细胞毒性作用的产品中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017070423A1 (en) * 2015-10-22 2017-04-27 Jounce Therapeutics, Inc. Gene signatures for determining icos expression
WO2018029474A2 (en) * 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
ES2612914T3 (es) 2011-03-31 2017-05-19 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos dirigidos contra Icos y usos de los mismos
CA2889182A1 (en) 2012-10-26 2014-05-01 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
SG11201506920QA (en) 2013-03-15 2015-09-29 Bristol Myers Squibb Co Ido inhibitors
TWI719970B (zh) 2015-03-23 2021-03-01 美商永斯醫療股份有限公司 針對ｉｃｏｓ之抗體
KR20260030924A (ko) 2016-08-09 2026-03-06 키맵 리미티드 항-icos 항체

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017070423A1 (en) * 2015-10-22 2017-04-27 Jounce Therapeutics, Inc. Gene signatures for determining icos expression
WO2018029474A2 (en) * 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025160816A (ja) * 2024-04-10 2025-10-23 イミューンオンコ バイオファーマシューティカルズ （シャンハイ） インコーポレイテッド 古典的ホジキンリンパ腫に対する併用療法

Also Published As

Publication number Publication date
US20190367613A1 (en) 2019-12-05
US11292840B2 (en) 2022-04-05
WO2019222188A1 (en) 2019-11-21
EP3793598A1 (en) 2021-03-24
US20220332823A1 (en) 2022-10-20
CN112703012A (zh) 2021-04-23

Similar Documents

Publication Publication Date Title
JP2021523213A (ja) 癌を治療する方法
JP7077226B2 (ja) Ｃｄ４７及びｅｇｆｒの二重標的化による癌治療
JP2023512837A (ja) Ｃｃｒ８に結合する抗体及び融合タンパク質並びにそれらの使用
JP2017508785A (ja) 癌を治療するためのｐｄ−１アンタゴニストおよびｉｄｏ１阻害剤の組み合わせ
US20220135682A1 (en) Anti-ICOS Antibodies for the Treatment of Cancer
KR20220116257A (ko) 골수섬유증 및 골수이형성 증후군을 치료하기 위한, 데시타빈 또는 항 pd-1 항체 스파르탈리주맙을 포함하거나 또는 포함하지 않는, 항 tim-3 항체 mbg453 및 항 tgf-베타 항체 nis793의 조합물
CN110678750A (zh) 用于癌症治疗的生物标志物
KR20220008253A (ko) 암을 앓는 대상에서 cd8+ t 세포 의존성 면역 반응을 향상시키기 위한 방법 및 약학적 조성물
CN117321418A (zh) 癌症生物标志物及其使用方法
JP2026004466A (ja) 限られた数のｎｋ細胞を有する患者における抗ｃｄ１９療法
KR20220066346A (ko) 항-il-27 항체 및 이의 용도
US20210353750A1 (en) Methods of Treating Cancer
JP2024512395A (ja) がんの治療のための方法
US20210355222A1 (en) Methods of Treating Cancer
AU2024361727A1 (en) Combination therapies with ulbp2 targeting antibodies for treating cancers
JP2023510847A (ja) 癌の治療方法
US20210380942A1 (en) Methods and compositions for the treatment of cancer and infectious diseases
JP2023510075A (ja) ヒト化抗ｃａ ｉｘ抗体、およびその使用方法
RU2825845C2 (ru) Применение антитела против pd-1 в изготовлении лекарственного средства для лечения солидных опухолей
HK40084229A (en) Treatment of cancer with dual targeting of cd47 and egfr
WO2025175166A1 (en) Combination therapies with btn1a1 binding proteins and chemotherapeutic agents
HK1259512A1 (en) Treatment of cancer with dual targeting of cd47 and egfr

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220512

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220512

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230509

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231205